Vestcor Inc grew its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,900 shares of the company's stock after buying an additional 3,300 shares during the period. Vestcor Inc's holdings in BioNTech were worth $1,128,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Jones Financial Companies Lllp raised its position in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. raised its position in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after purchasing an additional 700 shares during the last quarter. GAMMA Investing LLC raised its position in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after purchasing an additional 300 shares during the last quarter. Generali Investments CEE investicni spolecnost a.s. purchased a new position in BioNTech during the 4th quarter worth $137,000. Finally, AlphaCentric Advisors LLC purchased a new position in BioNTech during the 4th quarter worth $168,000. Institutional investors and hedge funds own 15.52% of the company's stock.
BioNTech Trading Up 0.3 %
NASDAQ BNTX traded up $0.31 during mid-day trading on Wednesday, hitting $99.27. The company's stock had a trading volume of 507,378 shares, compared to its average volume of 792,265. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The stock's fifty day simple moving average is $114.55 and its two-hundred day simple moving average is $113.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market capitalization of $23.80 billion, a P/E ratio of -47.27 and a beta of 0.30.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter last year, the firm posted $1.90 earnings per share. BioNTech's revenue for the quarter was down 19.5% compared to the same quarter last year. Research analysts expect that BioNTech SE will post -3.88 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. Berenberg Bank began coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a "buy" rating and a $130.00 price objective for the company. Truist Financial began coverage on shares of BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price target for the company. Morgan Stanley cut their price target on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. Wells Fargo & Company began coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price target for the company. Finally, BMO Capital Markets increased their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, BioNTech currently has a consensus rating of "Moderate Buy" and an average target price of $143.73.
Get Our Latest Stock Analysis on BioNTech
BioNTech Profile
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
See Also
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
